Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

0.8400
-0.0499-5.61%
Post-market: 0.8398-0.0002-0.02%18:49 EDT
Volume:71.46K
Turnover:62.28K
Market Cap:22.39M
PE:-2.94
High:0.9098
Open:0.8982
Low:0.8400
Close:0.8899
52wk High:3.40
52wk Low:0.8208
Shares:26.65M
Float Shares:21.83M
Volume Ratio:0.73
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.18
PE(LYR):-2.14

Loading ...

Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Dow Jones
·
Aug 13

ABVC Biopharma FY26 Q2 Net Loss Narrows 65% to $810,481

Reuters
·
Aug 13

ABVC BioPharma Delays BioKey (Cayman) Share Distribution to Aug. 21 from Aug. 3 in 8-K Amendment

Reuters
·
Aug 13

ABVC Biopharma - Biokey (Cayman) Share Distribution Rescheduled for August 21, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 13

ABVC Biopharma - Postpones Biokey (Cayman) Share Distribution - SEC Filing

THOMSON REUTERS
·
Aug 13

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

GlobeNewswire
·
Aug 11

Collegium Q2 2026 earnings: ADHD growth offsets pain portfolio pressure

TradingKey
·
Aug 07

Yukiguni Maitake Sees FY Net Y2.54b

Dow Jones
·
Aug 06

BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%

MT Newswires Live
·
Aug 05

NASDAQ Trade Halt Halt News Pending at 04:43 Pm

Reuters
·
Aug 04

Press Release: Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Dow Jones
·
Aug 03

BlinkLab requests ASX trading halt ahead of material ADHD study results

TIPRANKS
·
Aug 03

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 01

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

TIPRANKS
·
Aug 01

ABVC Biopharma Announces Special Shareholder Meeting

Reuters
·
Jul 29

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

GlobeNewswire
·
Jul 28

US FDA Approves Otsuka's Novel ADHD Drug Simtriyo for Market Launch

Deep News
·
Jul 28

Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003

TIPRANKS
·
Jul 22

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14